Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index; 83 of the 162 sources its claims cite were checked for support.

Primary biliary cholangitis.

Open access

Abstract

Narrative review of epidemiology, pathogenesis, and current and emerging treatment of PBC.

Overview

CoChat Summary

TL;DR

Primary biliary cholangitis is a chronic autoimmune cholestatic disease with rising incidence worldwide and a decreasing female-to-male ratio, driven by genetic susceptibility, environmental triggers, immune dysregulation, and biliary epithelial injury. Management now includes ursodeoxycholic acid, obeticholic acid, and PPAR agonists, with emerging goals of alkaline phosphatase normalisation and improved symptom-related quality of life.

Key findings

  • Pooled global incidence is 1·76 and prevalence 14·6 per 100 000 people per year; the female-to-male ratio has fallen from 9:1 to 4:1 over 20 years. Regional incidence is 2·75 in North America, 1·86 in Europe, and 0·84 in Asia-Pacific per 100 000 people per year, with prevalence 21·81, 14·59, and 9·82, respectively.
  • Diagnosis requires at least two of biochemical chronic cholestasis, positive anti-mitochondrial antibodies, and compatible histology; elevated alkaline phosphatase plus positive anti-mitochondrial antibody is sufficient without biopsy. Anti-gp210 and anti-sp100 have low sensitivities (23% and 25%) but high specificity (>95%) in anti-mitochondrial antibody-negative disease.
  • Ursodeoxycholic acid is standard of care: 10-year liver transplant-free survival was 79·7% with versus 60·7% without treatment, with a hazard ratio of 0·46 (95% CI 0·40–0·52, p<0·001). In phase 3 trials, elafibranor met the primary endpoint in 50·9% versus 3·8% with placebo, and seladelpar in 61·7% versus 20·0%; alkaline phosphatase normalisation occurred in 15% and 25%, respectively.
  • Hepatocellular carcinoma incidence is 3·4–3·6 per 1000 patient-years overall and 15·7 per 1000 patient-years in cirrhosis; osteoporosis risk is increased 3·3-fold. Fatigue affects more than 50% of patients and pruritus 20–80%.

Methods

  • Design: narrative Lancet Seminar/review, not primary research; it synthesises epidemiology, pathogenesis, diagnosis, and management of primary biliary cholangitis.
  • Data: published literature including meta-analyses, genome-wide association studies, randomised controlled trials (e.g., POISE, ELATIVE, RESPONSE), real-world cohorts, and clinical practice guidelines; no new patient sample or primary data collection.
  • Analysis: narrative synthesis with figures and tables summarising pathogenesis, diagnostic approach, and clinical trials of PPAR agonists and symptom-directed therapies.

Limitations

  • Stated: current data on the efficacy of combination therapy, particularly long-term prognosis and safety, are insufficient; evidence supporting bisphosphonate use for osteoporosis in primary biliary cholangitis remains insufficient; PPAR agonist phase 3 trials excluded patients with advanced fibrosis, so these agents are unlikely to be indicated in that group; and the benefit of alkaline phosphatase normalisation derives from retrospective ursodeoxycholic acid monotherapy data and requires prospective real-world validation for second-line therapies.
  • Evident from the text: as a narrative Seminar, no systematic search strategy, inclusion criteria, or risk-of-bias assessment is described, and many cited management and prognosis data are retrospective or real-world.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)01303-5

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

60 Valid · 9 Not valid · 58 Not checked · 35 Own results and interpretations

86 more claims · 37 with their cited sources checked

Create a free account to see all 162 claims and to verify the 7 references still open.

See all claims — free account
  • Borderline: one of the tests for a substantial claim is unclear. 2
  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 28

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 132 references

Cited by

See all 177

Metadata

Authors
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M.
Affiliations
  • Teikyo University (JP)
  • Shanghai Jiao Tong University (CN)
  • Fukushima Medical University (JP)
  • Baylor College of Medicine (US)
Corresponding author
Tanaka, Atsushi
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-09
Volume
404
Issue
10457
Pages
1053-1066
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4401936541
Cited by
177
References
132
Citations by year
2026: 92 · 2025: 77 · 2024: 8
FWCI
12.71
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Government of Japan Ministry of Health Labour and Welfare
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
primary biliary cirrhosis, autoimmune cholestatic liver disease, incidence trends, sex differences, gut microbiota, environmental triggers, pathogenesis, cholangiocytes, cytokines and chemokines, obeticholic acid, ursodeoxycholic acid, triple therapy, pruritus, fatigue, health-related quality of life, risk stratification, early diagnosis
MeSH terms
Gastrointestinal Microbiome, Aged, Chenodeoxycholic Acid, Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Ursodeoxycholic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary biliary cholangitis. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01303-5
The paper
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024). Primary biliary cholangitis. The Lancet. https://doi.org/10.1016/s0140-6736(24)01303-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.